网站标志
导航菜单
购物车
购物车 0 件商品 | 查看购物车 | 我的订单 | 我的积分 | 会员中心
当前日期时间
当前时间:
商品搜索
商品搜索:
价格
点评详情
点评详情
发布于:2018-5-5 10:05:38  访问:0 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
This Is The Swift Method To Succeed Using Panobinostat
5, 20 With the increased importance in HPV-positive OPSCC, we sought to determine whether or not practicing radiation oncologists across the United States have instituted HPV DNA analysis or p16 immunohistochemical staining into their practices, because little is known regarding its status in clinical use. We conducted a national online survey of practicing radiation oncologists to address this issue, and the results are reported here. Five hundred forty-two radiation oncologists were selected check details randomly from approximately 9000 members in the 2008 American Society of Therapeutic Radiation Oncology directory. Surveys were sent to physicians from all 50 states and the District of Columbia. Physicians were excluded if they were emeritus, junior physicians in training, or in international practice. Only 1 physician per practice was contacted. From February 2, 2009 to February 24, 2009, e-mail surveys were sent to 542 radiation oncologists; however, 58 surveys were undeliverable or were marked as spam; therefore, 484 physicians were contactable. Two reminder e-mails were sent to increase the response rate. Each physician was sent an 11-question Selleck Selumetinib survey. The complete survey is provided in Table 1. Each e-mail contained a cover letter that explained the purpose and content of the survey, provided an online link to access the survey, explained the confidentiality of the survey, and provided an optional link to request removal from the e-mail list. The survey inquired about the number of patients with OC treated per year, the number of physicians Panobinostat in the practice, the location of the practice, the practice type (academic vs private institution), when neck dissections are performed, the use of intensity-modulated radiotherapy (IMRT) for head and neck cancer, screening for HPV DNA or p16 in oropharyngeal pathologic specimens, and the use of HPV or p16 data to direct patient care. Respondents who do not screen for HPV DNA or p16 were asked about future plans to institute these screening techniques. Those who already had instituted screening were asked to indicate the year that such screening began. The results of the survey were analyzed in February 2009. Survey responses were analyzed if the survey was at least partially completed. The percentages are presented based on evaluable responses. SPSS statistical software (version 16.0) was used for statistical analysis (SPSS Inc, Chicago, Ill). A chi-square test was used to analyze differences in proportions between various groups. All P values <.05 were considered significant. Of the 484 contactable physicians, we received 192 responses (39.6%). Responses were received from physicians in 47 states and the District of Columbia. Fifty-three responses (27.6%) were from academic physicians, and 139 responses (72.4%) were from physicians in private practice. Figures 1 through 3 illustrate the characteristics of the survey population.
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
我要回复
回复内容
验 证 码
看不清?更换一张
匿名发表 
脚注信息
Copyright (C) 2015-2016 All Rights Reserved. 光明云南石斛商城管理系统 版权所有   滇ICP备11005439号-1
服务时间:周一至周日 09:00 — 18:00  全国订购及服务热线:0691-5161027 
联系地址:云南省西双版纳傣族自治州勐海县工业园区   邮政编码:666200